Targets › TNFRSF6B
1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Mar 2027.
Soluble decoy receptor that binds and neutralizes the TNF-family ligands TNFSF14/LIGHT, TNFSF15, and FASLG, preventing them from interacting with their cognate receptors and thereby blocking apoptosis and other immune-signaling pathway. (UniProt, O95407)
Open in Phaseline: the race on TNFRSF6B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Julie Gehl | Bleomycin DNA-damaging chemotherapy agent; bleomycin causes DNA strand breaks and inhibits DNA synth | TNFRSF6B | Phase 4 | Cutaneous Metastasis | Mar 2027 |
Cutaneous Metastasis (1)
small molecule (1)
Julie Gehl (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.